Evaluation of Oritavancin in Combination with Rifampin, Gentamicin or Linezolid Against Prosthetic Joint Infection-Associated Methicillin-Resistant Staphylococcus aureus Biofilms by Time-Kill Assays [PublishAheadOfPrint]

The anti-biofilm activity of oritavancin in combination with rifampin, gentamicin or linezolid was evaluated against ten prosthetic joint infection (PJI) related methicillin-resistant Staphylococcus aureus (MRSA) by time-kill assays. Oritavancin combined with rifampin demonstrated statistically significant bacterial reductions compared to either antimicrobial alone for all ten isolates (P ≤0.001), with synergy being observed for 80% (8/10) of the isolates. Oritavancin and rifampin combination therapy may be an option for treating MRSA PJI.

https://ift.tt/2zKJWxk